Cargando…

Synchronous Breast Cancer: Phenotypic Similarities on MRI

BACKGROUND: Previous studies have shown discrepancies between index and synchronous breast cancer in histology and molecular phenotype. It is yet unknown whether this observation also applies to the MRI phenotype. PURPOSE: To investigate whether the appearance of breast cancer on MRI (i.e. phenotype...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hui, van der Velden, Bas H.M., Chan, Hui Shan M., Loo, Claudette E., Viergever, Max A., Gilhuijs, Kenneth G.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318126/
https://www.ncbi.nlm.nih.gov/pubmed/31854487
http://dx.doi.org/10.1002/jmri.27026
_version_ 1783550773684076544
author Wang, Hui
van der Velden, Bas H.M.
Chan, Hui Shan M.
Loo, Claudette E.
Viergever, Max A.
Gilhuijs, Kenneth G.A.
author_facet Wang, Hui
van der Velden, Bas H.M.
Chan, Hui Shan M.
Loo, Claudette E.
Viergever, Max A.
Gilhuijs, Kenneth G.A.
author_sort Wang, Hui
collection PubMed
description BACKGROUND: Previous studies have shown discrepancies between index and synchronous breast cancer in histology and molecular phenotype. It is yet unknown whether this observation also applies to the MRI phenotype. PURPOSE: To investigate whether the appearance of breast cancer on MRI (i.e. phenotype) is different from that of additional breast cancer (i.e. synchronous cancer), and whether such a difference, if it exists, is associated with prognosis. STUDY TYPE: Retrospective. POPULATION: In all, 464 consecutive patients with early‐stage ER+/HER2– breast cancer were included; 34/464 (7.3%) had 44 synchronous cancers in total (34 ipsilateral, 10 contralateral). SEQUENCE: 1.5T, contrast‐enhanced T(1)‐weighted. ASSESSMENT: We assessed imaging phenotype using 50 quantitative features from each cancer and applied principal component analysis (PCA) to identify independent properties. The degree of phenotype difference was assessed. An association between phenotype differences and prognosis in terms of the Nottingham Prognostic Index (NPI) and PREDICT score were analyzed. STATISTICAL TESTS: PCA; Wilcoxon rank sum test; Benjamini–Hochberg to control the false discovery rate. RESULTS: PCA identified eight components in patients with ipsilateral synchronous cancer. Six out of eight were significantly different between index and synchronous cancer. These components represented features describing texture (three components, P < 0.001, P < 0.001, P = 0.004), size (P < 0.001), smoothness (P < 0.001), and kinetics (P = 0.004). Phenotype differences in terms of the six components were split in tertiles. Larger phenotype differences in size, kinetics, and texture were associated with significantly worse prognosis in terms of NPI (P = 0.019, P = 0.045, P = 0.014), but not for the PREDICT score (P = 0.109, P = 0.479, P = 0.109). PCA identified six components in patients with contralateral synchronous cancer. None were significantly different from the index cancer (P = 0.178, P = 0.178, P = 0.178, P = 0.326, P = 0.739, P = 0.423). DATA CONCLUSION: The MRI phenotype of ER+/HER2– breast cancer was different from that of ipsilateral synchronous cancer and a large phenotype difference was associated with worse prognosis. No significant difference was found for synchronous contralateral cancer. Level of Evidence: 3 Technical Efficacy: Stage 4 J. Magn. Reson. Imaging 2020;51:1858–1867.
format Online
Article
Text
id pubmed-7318126
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-73181262020-06-29 Synchronous Breast Cancer: Phenotypic Similarities on MRI Wang, Hui van der Velden, Bas H.M. Chan, Hui Shan M. Loo, Claudette E. Viergever, Max A. Gilhuijs, Kenneth G.A. J Magn Reson Imaging Original Research BACKGROUND: Previous studies have shown discrepancies between index and synchronous breast cancer in histology and molecular phenotype. It is yet unknown whether this observation also applies to the MRI phenotype. PURPOSE: To investigate whether the appearance of breast cancer on MRI (i.e. phenotype) is different from that of additional breast cancer (i.e. synchronous cancer), and whether such a difference, if it exists, is associated with prognosis. STUDY TYPE: Retrospective. POPULATION: In all, 464 consecutive patients with early‐stage ER+/HER2– breast cancer were included; 34/464 (7.3%) had 44 synchronous cancers in total (34 ipsilateral, 10 contralateral). SEQUENCE: 1.5T, contrast‐enhanced T(1)‐weighted. ASSESSMENT: We assessed imaging phenotype using 50 quantitative features from each cancer and applied principal component analysis (PCA) to identify independent properties. The degree of phenotype difference was assessed. An association between phenotype differences and prognosis in terms of the Nottingham Prognostic Index (NPI) and PREDICT score were analyzed. STATISTICAL TESTS: PCA; Wilcoxon rank sum test; Benjamini–Hochberg to control the false discovery rate. RESULTS: PCA identified eight components in patients with ipsilateral synchronous cancer. Six out of eight were significantly different between index and synchronous cancer. These components represented features describing texture (three components, P < 0.001, P < 0.001, P = 0.004), size (P < 0.001), smoothness (P < 0.001), and kinetics (P = 0.004). Phenotype differences in terms of the six components were split in tertiles. Larger phenotype differences in size, kinetics, and texture were associated with significantly worse prognosis in terms of NPI (P = 0.019, P = 0.045, P = 0.014), but not for the PREDICT score (P = 0.109, P = 0.479, P = 0.109). PCA identified six components in patients with contralateral synchronous cancer. None were significantly different from the index cancer (P = 0.178, P = 0.178, P = 0.178, P = 0.326, P = 0.739, P = 0.423). DATA CONCLUSION: The MRI phenotype of ER+/HER2– breast cancer was different from that of ipsilateral synchronous cancer and a large phenotype difference was associated with worse prognosis. No significant difference was found for synchronous contralateral cancer. Level of Evidence: 3 Technical Efficacy: Stage 4 J. Magn. Reson. Imaging 2020;51:1858–1867. John Wiley & Sons, Inc. 2019-12-19 2020-06 /pmc/articles/PMC7318126/ /pubmed/31854487 http://dx.doi.org/10.1002/jmri.27026 Text en © 2019 The Authors. Journal of Magnetic Resonance Imaging published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Wang, Hui
van der Velden, Bas H.M.
Chan, Hui Shan M.
Loo, Claudette E.
Viergever, Max A.
Gilhuijs, Kenneth G.A.
Synchronous Breast Cancer: Phenotypic Similarities on MRI
title Synchronous Breast Cancer: Phenotypic Similarities on MRI
title_full Synchronous Breast Cancer: Phenotypic Similarities on MRI
title_fullStr Synchronous Breast Cancer: Phenotypic Similarities on MRI
title_full_unstemmed Synchronous Breast Cancer: Phenotypic Similarities on MRI
title_short Synchronous Breast Cancer: Phenotypic Similarities on MRI
title_sort synchronous breast cancer: phenotypic similarities on mri
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318126/
https://www.ncbi.nlm.nih.gov/pubmed/31854487
http://dx.doi.org/10.1002/jmri.27026
work_keys_str_mv AT wanghui synchronousbreastcancerphenotypicsimilaritiesonmri
AT vanderveldenbashm synchronousbreastcancerphenotypicsimilaritiesonmri
AT chanhuishanm synchronousbreastcancerphenotypicsimilaritiesonmri
AT looclaudettee synchronousbreastcancerphenotypicsimilaritiesonmri
AT viergevermaxa synchronousbreastcancerphenotypicsimilaritiesonmri
AT gilhuijskennethga synchronousbreastcancerphenotypicsimilaritiesonmri